Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection

The purpose of this parallel treatment group, double-blind. multicenter study was to lharacterize the pharmacokinetics of nevirapine and lamivudine when coadministered to patients with the HIV-1 infection. This pharmacokinetic interaction study was nested within a larger Phase III clinical trial conducted to characterize the safety and efficacy of coadministered nevirapine and lamivudine. One hundred HIV-1 infected patients with CD4+ lymphocyte counts=200 cells/mm3 and who were on a background of nucleoside (zidovudine [ZDV], didanosine [ddl], zalcitabine [ddC], stavudine [d4T]) therapy were randomly assigned to be treated with either nucleoside+ lamivudine+nevirapine or nucleoside+lamivudine+ placebo. Each patient underwent blood sampling at defined times for the purpose of determining the concentration of nevirapine in plasma and lamivudine in serum under steady-state conditions. Each patient was also monitored closely for concomitant administration of other drugs, including ZDV, ddl, ddC, d4T and cotrimoxazole. The pharmacokinetics of nevirapine and lamivudine were characterized using nonlinear mixed-effects modeling. There were no reported serious adverse events during the 40-day pharmacokinetic study. The results of the modeling analysis revealed that nevirapine had no effect on the pharmacokinetics of lamivudine. Estimates of the apparent clearance for nevirapine (CL/F=3.3 L/hour; 95% confidence interval [Cl] 2.9 to 3.7 L/hour) and lamivudine (CL/F 27.6 L/hour; 95% Cl 22 to 33.2 L/hour) were consistent with the values reported in earlier trials. However, the results also showed that concomitant administration of lamivudine with cotrimoxazole resulted in a 31% reduction in the apparent clearance of lamivudine, resulting in a 43% increase in the average steady-state lamivudine serum concentrations. These results indicate that chronic concurrent administration of cotrimoxazole with lamivudine may significantly affect the steady-state pharmacokinetics of lamivudine.

[1]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[2]  R. Murphy,et al.  Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. , 1999, The Journal of infectious diseases.

[3]  S. Danner,et al.  The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a Phase I study , 1992, AIDS.

[4]  R. Douglas Martin,et al.  S-PLUS Version 3 , 1992 .

[5]  G. E. Pakes,et al.  Clinical Pharmacokinetics of Lamivudine , 1999, Clinical pharmacokinetics.

[6]  D. Kuritzkes,et al.  Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter , 1995 .

[7]  J. Pav,et al.  HPLC-UV method for the quantitation of nevirapine in biological matrices following solid phase extraction. , 1999, Journal of pharmaceutical and biomedical analysis.

[8]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[9]  T. Macgregor,et al.  Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers , 1999, Biopharmaceutics & drug disposition.

[10]  T. Greenough,et al.  High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. , 1995, The Journal of infectious diseases.

[11]  David Back,et al.  Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection , 1999, Clinical pharmacokinetics.

[12]  J. Montaner,et al.  Drug Evaluations Anti-infectives: Nevirapine: A review of its development, pharmacological profile and potential for clinical use , 1996 .

[13]  T. Macgregor,et al.  Disposition and biotransformation of the antiretroviral drug nevirapine in humans. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[14]  P. Statkevich,et al.  Renal Disposition and Drug Interaction Screening of (–)-2′-deoxy-3′-thiacytidine (3TC) in the Isolated Perfused Rat Kidney , 1995, Pharmaceutical Research.

[15]  J. Eron,et al.  Pharmacokinetics of lamivudine administered alone and with trimethoprim‐sulfamethoxazole , 1996, Clinical pharmacology and therapeutics.

[16]  M. Polis,et al.  Drug interactions in patients infected with human immunodeficiency virus. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.